ZMC(SH:600216) Shang Hai Zheng Quan Bao·2025-04-18 22:09Core Viewpoint - Zhejiang Pharmaceutical Co., Ltd. plans to repurchase shares through centralized bidding, with the aim of enhancing investor confidence and aligning the company's stock price with its intrinsic value [1][4][5] Summary by Sections Repurchase Plan Overview - The repurchase will involve the company's issued ordinary shares (A-shares) [6] - The repurchase method will be through centralized bidding [7] - The total funds allocated for the repurchase will be between RMB 100 million and RMB 200 million [11] - The maximum repurchase price is set at RMB 20.83 per share, which is 150% of the average trading price over the previous 30 trading days [12] - The funding source will be the company's own funds or self-raised funds [13] - The repurchase period is from April 15, 2025, to April 14, 2026 [8] Purpose and Impact of the Repurchase - The purpose of the repurchase is to enhance investor confidence, align stock price with intrinsic value, and improve the long-term incentive mechanism for management and key employees [5][15] - If the repurchased shares are not utilized within 36 months, they will be canceled [19] Financial Implications - As of September 30, 2024, the company's total assets were RMB 13.43 billion, with net assets of RMB 10.34 billion and a debt-to-asset ratio of 21% [15] - The repurchase will have a minimal impact on the company's daily operations and financial health [15] Shareholder and Management Plans - The actual controller and chairman, Li Nanhang, proposed the repurchase based on confidence in the company's future [4][19] - There are no plans for share sales by the company's directors, supervisors, or major shareholders in the next three to six months [18][19] Regulatory Compliance and Procedures - The repurchase plan was approved by the board of directors and complies with relevant regulations [4][10] - The company has established a dedicated securities account for the repurchase [23]